Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Conditions
Interventions
Tofacitinib 5 mg BID
Tofacitinib 10 mg BID
+3 more
Locations
123
United States
Rheumatology Associates, PC
Birmingham, Alabama, United States
Rheumatology Associates of North Alabama, PC
Huntsville, Alabama, United States
Arizona Arthritis & Rheumatology Associates, P.C.
Glendale, Arizona, United States
Medvin Clinical Research
Covina, California, United States
Desert Medical Advances
Palm Desert, California, United States
Advances In Medicine (X-Rays)
Rancho Mirage, California, United States
Start Date
January 20, 2014
Primary Completion Date
December 18, 2015
Completion Date
December 18, 2015
Last Updated
July 6, 2017
NCT07486960
NCT07536529
NCT07295509
NCT07286058
NCT06100744
NCT04402086
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions